CanSino Biologics Valuation
| CJH Stock | EUR 3.58 0.26 7.83% |
At this time, the firm appears to be overvalued. CanSino Biologics shows a prevailing Real Value of €3.38 per share. The current price of the firm is €3.58. Our model approximates the value of CanSino Biologics from analyzing the firm fundamentals such as Shares Owned By Insiders of 26.70 %, current valuation of 3.4 B, and Return On Equity of 0.0111 as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that CanSino Biologics' price fluctuation is very risky at this time. Calculation of the real value of CanSino Biologics is based on 3 months time horizon. Increasing CanSino Biologics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the CanSino stock is determined by what a typical buyer is willing to pay for full or partial control of CanSino Biologics. Since CanSino Biologics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of CanSino Stock. However, CanSino Biologics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.58 | Real 3.38 | Hype 3.58 | Naive 2.92 |
The real value of CanSino Stock, also known as its intrinsic value, is the underlying worth of CanSino Biologics Company, which is reflected in its stock price. It is based on CanSino Biologics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of CanSino Biologics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of CanSino Biologics helps investors to forecast how CanSino stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of CanSino Biologics more accurately as focusing exclusively on CanSino Biologics' fundamentals will not take into account other important factors: CanSino Biologics Total Value Analysis
CanSino Biologics is currently estimated to have takeover price of 3.4 B with market capitalization of 3.15 B, debt of 40 M, and cash on hands of 6.71 B. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the CanSino Biologics fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
3.4 B | 3.15 B | 40 M | 6.71 B |
CanSino Biologics Investor Information
About 27.0% of the company shares are held by company insiders. The book value of CanSino Biologics was currently reported as 29.22. The company last dividend was issued on the 13th of July 2022. Based on the key indicators related to CanSino Biologics' liquidity, profitability, solvency, and operating efficiencyBased on the analysis of, CanSino Biologics is not in a good financial situation at the moment. It has a very high risk of going through financial straits in January.CanSino Biologics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. CanSino Biologics has an asset utilization ratio of 36.21 percent. This implies that the Company is making €0.36 for each dollar of assets. An increasing asset utilization means that CanSino Biologics is more efficient with each dollar of assets it utilizes for everyday operations.CanSino Biologics Ownership Allocation
CanSino Biologics holds a total of 114.78 Million outstanding shares. CanSino Biologics retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.CanSino Biologics Profitability Analysis
The company reported the revenue of 4.3 B. Net Income was 1.91 B with profit before overhead, payroll, taxes, and interest of 1.03 B.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates CanSino Biologics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in CanSino Biologics and how it compares across the competition.
About CanSino Biologics Valuation
The stock valuation mechanism determines CanSino Biologics' current worth on a weekly basis. Our valuation model uses a comparative analysis of CanSino Biologics. We calculate exposure to CanSino Biologics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of CanSino Biologics's related companies.CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the Peoples Republic of China. CanSino Biologics Inc. was founded in 2009 and is headquartered in Tianjin, the Peoples Republic of China. CANSINO BIOLOGICS operates under Drug ManufacturersSpecialty Generic classification in Germany and is traded on Frankfurt Stock Exchange. It employs 726 people.
8 Steps to conduct CanSino Biologics' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates CanSino Biologics' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct CanSino Biologics' valuation analysis, follow these 8 steps:- Gather financial information: Obtain CanSino Biologics' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine CanSino Biologics' revenue streams: Identify CanSino Biologics' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research CanSino Biologics' industry and market trends, including the size of the market, growth rate, and competition.
- Establish CanSino Biologics' growth potential: Evaluate CanSino Biologics' management, business model, and growth potential.
- Determine CanSino Biologics' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate CanSino Biologics' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Complementary Tools for CanSino Stock analysis
When running CanSino Biologics' price analysis, check to measure CanSino Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CanSino Biologics is operating at the current time. Most of CanSino Biologics' value examination focuses on studying past and present price action to predict the probability of CanSino Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CanSino Biologics' price. Additionally, you may evaluate how the addition of CanSino Biologics to your portfolios can decrease your overall portfolio volatility.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |